A Phase 3 interventional study of Comparator: ezetimibe/simvastatin + niacin (ER) and Comparator: Placebo to ezetimibe/simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 4th largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 50 in phase 3, and was the 13th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 14 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,220 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 10th largest by enrollment of the 81 interventional ones that give a count, is one of 17 that started in 2005, is one of 58 in phase 3, and was the 24th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ezetimibe/simvastatin combination tablet + niacin (ER)
Drug: Comparator: ezetimibe/simvastatin + niacin (ER)
ezetimibe/simvastatin
Drug: Comparator: ezetimibe (+) simvastatin · Drug: Comparator: Placebo to Niacin (ER)
Niacin (ER)
Drug: Comparator: Placebo to ezetimibe/simvastatin · Drug: Comparator: niacin (ER) tablet
ezetimibe/simvastatin combination tablet + niacin (ER)
Drug: Comparator: ezetimibe/simvastatin and niacin (ER)
ezetimibe/simvastatin combination tablet + niacin (Pbo)
Drug: Comparator: ezetimibe and simvastatin · Drug: Comparator: Placebo to niacin (ER)
Drug pages: Ezetimibe · Simvastatin · Niacin
ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.
niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.
Drug pages: Ezetimibe · Simvastatin · Niacin
ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline
Time frame: Baseline and 24 Weeks
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline
Time frame: Baseline and 24 weeks
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline
Time frame: Baseline and 24 weeks
Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline
Time frame: Baseline and 24 weeks
Percent Change From Baseline in Triglycerides (TG)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline
Time frame: baseline and 24 Weeks
Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline
Time frame: Baseline and 64 weeks
Percent Change From Baseline in Triglycerides (TG)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline
Time frame: Baseline and 64 weeks
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline
Time frame: Baseline and 64 weeks
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline
Time frame: Baseline and 64 weeks
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline
Time frame: Baseline and 24 weeks
| Milestone | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|---|
| Started | 272 | 272 | 676 |
| Completed | 166 | 213 | 391 |
| Not completed | 106 | 59 | 285 |
| Withdrew: Adverse event | 68 | 25 | 156 |
| Withdrew: Lost to follow-up | 6 | 8 | 24 |
| Withdrew: Protocol violation | 5 | 4 | 7 |
| Withdrew: Patient moved | 3 | 1 | 5 |
| Withdrew: Withdrawal by subject | 23 | 17 | 45 |
| Withdrew: Ldl < 50 mg/dl | 1 | 4 | 48 |
| Milestone | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|---|
| Started | 0 | 266 | 485 |
| Completed | 0 | 234 | 401 |
| Not completed | 0 | 32 | 84 |
| Withdrew: Adverse event | 0 | 17 | 33 |
| Withdrew: Lack of efficacy | 0 | 1 | 6 |
| Withdrew: Lost to follow-up | 0 | 6 | 18 |
| Withdrew: Protocol violation | 0 | 3 | 5 |
| Withdrew: Patient moved | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 2 | 13 |
| Withdrew: Ldl < 50 mg/dl | 0 | 3 | 4 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline
| Percent change | Niacin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) | -20.1 ± 1.3 | -58.5 ± 0.8 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline
| Percent change | Niacin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) | -22.0 ± 1.3 | -55.6 ± 0.8 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C) | 8.1 ± 1.3 | 30.2 ± 1.0 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) | 23.7 ± 29.7 | -42.5 ± 27.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C) | 9.0 ± 1.4 | 30.5 ± 1.1 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) | -26.8 ± 32.7 | -44.5 ± 26.9 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) | -45.1 ± 1.3 | -52.4 ± 0.9 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) | -49.3 ± 1.3 | -54.0 ± 1.0 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) | -53.5 ± 1.2 | -58.5 ± 0.8 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline
| Percent change | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin |
|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) | -47.9 ± 1.1 | -55.6 ± 0.8 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niacin | — | — | — |
| Ezetimibe/Simvastatin | — | — | — |
| Ezetimibe/Simvastatin + Niacin | — | — | — |
| Ezetimibe/Simvastatin - Part 2 | — | — | — |
| Ezetimibe/Simvastatin + Niacin - Part 2 | — | — | — |
| Event | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin | Ezetimibe/Simvastatin - Part 2 | Ezetimibe/Simvastatin + Niacin - Part 2 |
|---|---|---|---|---|---|
| Cerebrovascular AccidentNervous system disorders | 2/272 | 0/272 | 0/670 | 1/326 | 0/775 |
| Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/272 | 0/272 | 0/670 | 2/326 | 2/775 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/272 | 0/272 | 0/670 | 0/326 | 4/775 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/272 | 0/272 | 2/670 | 0/326 | 3/775 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/272 | 0/272 | 2/670 | 1/326 | 3/775 |
| SyncopeNervous system disorders | 0/272 | 0/272 | 2/670 | 0/326 | 3/775 |
| Acute Coronary SyndromeCardiac disorders | 0/272 | 1/272 | 1/670 | 1/326 | 1/775 |
| Atrial FibrillationCardiac disorders | 0/272 | 1/272 | 0/670 | 0/326 | 1/775 |
| SpondylolisthesisCongenital, familial and genetic disorders | 0/272 | 1/272 | 0/670 | 1/326 | 0/775 |
| Chest PainGeneral disorders | 1/272 | 1/272 | 0/670 | 1/326 | 1/775 |
| Event | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin | Ezetimibe/Simvastatin - Part 2 | Ezetimibe/Simvastatin + Niacin - Part 2 |
|---|---|---|---|---|---|
| FlushingVascular disorders | 15/272 | 274/670 | 108/272 | 17/326 | 288/775 |
| PruritusSkin and subcutaneous tissue disorders | 4/272 | 79/670 | 35/272 | 4/326 | 86/775 |
| Upper Respiratory Tract InfectionInfections and infestations | 13/272 | 27/670 | 9/272 | 24/326 | 56/775 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/272 | 18/670 | 8/272 | 20/326 | 31/775 |
| DiarrhoeaGastrointestinal disorders | 9/272 | 27/670 | 10/272 | 12/326 | 47/775 |
| RashSkin and subcutaneous tissue disorders | 4/272 | 32/670 | 15/272 | 6/326 | 41/775 |
| SinusitisInfections and infestations | 7/272 | 21/670 | 5/272 | 17/326 | 35/775 |
| ParaesthesiaNervous system disorders | 2/272 | 25/670 | 14/272 | 4/326 | 29/775 |
| NasopharyngitisInfections and infestations | 9/272 | 16/670 | 9/272 | 15/326 | 33/775 |
| HeadacheNervous system disorders | 8/272 | 13/670 | 12/272 | 14/326 | 18/775 |
| Age, Continuous(years) | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin | Total |
|---|---|---|---|---|
| Mean | 56.4 ± 10.6 | 57.5 ± 10.3 | 56.9 ± 10.9 | 56.9 ± 10.7 |
| Sex: Female, Male(Participants) | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin | Total |
|---|---|---|---|---|
| Female | 136 | 120 | 352 | 608 |
| Male | 136 | 152 | 324 | 612 |
| Race/Ethnicity, Customized(participants) | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin | Total |
|---|---|---|---|---|
| Asian | 11 | 4 | 11 | 26 |
| Black | 13 | 17 | 38 | 68 |
| Hispanic | 14 | 11 | 49 | 74 |
| Other | 3 | 0 | 2 | 5 |
| White | 231 | 240 | 576 | 1047 |
| Body Mass Index(Participants) | Niacin | Ezetimibe/Simvastatin | Ezetimibe/Simvastatin + Niacin | Total |
|---|---|---|---|---|
| <25 kg/m2 | 48 | 39 | 135 | 222 |
| 25 to <30 kg/m2 | 110 | 119 | 252 | 481 |
| 30 to <40 kg/m2 | 97 | 94 | 251 | 442 |
| ≥ 40 kg/m2 | 16 | 19 | 34 | 69 |
| No BMI Data | 1 | 1 | 4 | 6 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Dec 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin · Niacin